よむ、つかう、まなぶ。
総－５参考５ (14 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_74036.html |
| 出典情報 | 中央社会保険医療協議会 総会（第651回 6／24）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol.
2023;8(2):179-91.
13
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy
and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
14
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease.
Nat Rev Gastroenterol Hepatol. 2019;16(6):377-86.
15
Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, et al. Effect
of semaglutide on liver enzymes and markers of inflammation in subjects with
type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019;50(2):193-203.
16
Jara M, Norlin J, Kjær MS, Almholt K, Bendtsen KM, Bugianesi E, et al.
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in
metabolic dysfunction-associated steatohepatitis. Nat Med. 2025.
17
Newsome P. N, Armstrong M. J, Bakulin I, Belloum A, Cali A M, Geerts A, et al.
Weight-independent benefits of semaglutide on histology and non-invasive tests in
participants with biopsy-defined metabolic dysfunction-associated steatohepatitis:
Post hoc analysis of the essence trial part 1. United European Gastroenterology
Journal. 2025.13:S7-S188, 2025.
18
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6.
Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care.
2023;46(Suppl 1):S97-S110.
19
The Japan Society of Hepatology e. Guidance for Liver Biopsy. Tokyo: Nankodo.
2024.
13
2023;8(2):179-91.
13
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy
and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
14
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease.
Nat Rev Gastroenterol Hepatol. 2019;16(6):377-86.
15
Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, et al. Effect
of semaglutide on liver enzymes and markers of inflammation in subjects with
type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019;50(2):193-203.
16
Jara M, Norlin J, Kjær MS, Almholt K, Bendtsen KM, Bugianesi E, et al.
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in
metabolic dysfunction-associated steatohepatitis. Nat Med. 2025.
17
Newsome P. N, Armstrong M. J, Bakulin I, Belloum A, Cali A M, Geerts A, et al.
Weight-independent benefits of semaglutide on histology and non-invasive tests in
participants with biopsy-defined metabolic dysfunction-associated steatohepatitis:
Post hoc analysis of the essence trial part 1. United European Gastroenterology
Journal. 2025.13:S7-S188, 2025.
18
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6.
Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care.
2023;46(Suppl 1):S97-S110.
19
The Japan Society of Hepatology e. Guidance for Liver Biopsy. Tokyo: Nankodo.
2024.
13